@MoHFW_INDIA Bariatric surgeons as a group and subspecialists are most experienced in treating patients with obesity.Why have they been left out? Need urgent correction of this regulation.
Look at global salary data and one thing is obvious:
Developed nations value doctors. India consumes them.
Here, doctors are expected to:
•Work longer
•Earn less
•Stay silent
•And call it “nobility”
Abroad, the same doctor is called a high-value professional.
The gap isn’t competence.
The gap is respect—and regulation.
#DoctorsOfIndia
#IndianDoctors
#DoctorLivesMatter
#RespectDoctors
#ValueDoctors
#UnderpaidDoctors
#PayDoctorsFairly
#DoctorExploitation
#HealthcareCrisis
#BrokenHealthcare
A good hindi thriller series to binge watch over the weekend or Holidays, @MadhuriDixit steals the show,proves yet again she's a timeless legend #MrsDeshpandeOnJioHotstar
@DrDeepakKrishn1 Probably a retrocaecal one with plenty of adhesions..still 6hrs is a long time..Max 2-3hrs in difficult cases.Convert to open if the struggle is real.Regardless we shouldn't focus on the time,as long as the end result is that the patient has recovered well sir
@karthik2k2 Fantastic.Such stories re affirms the efficacy of multi modality treatment for obesity done under the right guidance & that Bariatric surgery is truly a life saving surgery.If only all endocrinologists & physicians where as persistent as u wer.
🚨 GLP-1s vs Surgery: Who Wins Long Term?
- - -
A new 2-year comparative study from NYU Langone just dropped—and the results are clear:
📊 Bariatric Surgery vs GLP-1s (semaglutide/tirzepatide):
🔹 25.7% total body weight loss with surgery vs 5.3% with GLP-1s (intention-to-treat)
🔹 Even in per-protocol analysis (continuous GLP-1 use), surgery still outperformed: 24.6% vs 7.6%
🔹 Surgery had better HbA1c improvement, too
🔍 Translational Insight:
Yes, the relatively low weight loss in the medication group was partly due to therapy interruptions and discontinuation. But that’s exactly the point:
➡️ If a treatment is regularly interrupted by prior auths, high out-of-pocket costs, or drug shortages, that limits its real-world effectiveness.
➡️ Clinical effectiveness ≠ theoretical efficacy in a vacuum. Access matters.
📌 Bottom line:
For patients with severe obesity (BMI ≥35), bariatric surgery still provides superior long-term outcomes—and it does so reliably, without being derailed by market forces.
Abstract: https://t.co/NlOas6X8j6
Great to hear a eminent voice from the healthcare community in Parliament articulate the problems and appropriate solutions for our ailing rural healthcare system
ರಾಷ್ಟ್ರೀಯ ಆರೋಗ್ಯ ಅಭಿಯಾನದಡಿ ಗುತ್ತಿಗೆ ಆಧಾರದ ಮೇಲೆ ಕಾರ್ಯನಿರ್ವಹಿಸುತ್ತಿರುವ ವೈದ್ಯರು ಮತ್ತು ಸ್ಟಾಫ್ ನರ್ಸ್ ಗಳ ಪ್ರಸ್ತುತ ವೇತನವನ್ನು ಹೆಚ್ಚಳ ಮಾಡುವಂತೆ ಕಳೆದ 4-5 ತಿಂಗಳುಗಳಿಂದ ನಿರಂತರವಾಗಿ ಕೇಂದ್ರ ಸರ್ಕಾರಕ್ಕೆ ಮನವಿ ಸಲ್ಲಿಸಿದೆ. ಈ ಬಗ್ಗೆ ಸಂಸತ್ ಅಧಿವೇಶನ ಸೇರಿದಂತೆ ಆರೋಗ್ಯ ಸ್ಥಾಯಿ ಸಮಿತಿ ಸಭೆಯಲ್ಲೂ ಸುದೀರ್ಘವಾಗಿ ವಿಷಯ ಪ್ರಸ್ತಾಪಿಸಿ ಈ ಬಗ್ಗೆ ಕ್ರಮ ವಹಿಸುವಂತೆ ಮನವಿ ಮಾಡಿದ್ದೆ, ಕೇಂದ್ರ ಆರೋಗ್ಯ ಸಚಿವರಾದ ಶ್ರೀ @JPNadda ಮತ್ತು ಪ್ರಧಾನಮಂತ್ರಿಗಳಾದ ಶ್ರೀ @narendramodi ಅವರಿಗೂ ವೈಯುಕ್ತಿಕವಾಗಿ ಈ ಬಗ್ಗೆ ಮನವಿ ಸಲ್ಲಿಸಿದೆ.
ಇದೀಗ ಕೇಂದ್ರ ಸರ್ಕಾರ NHM ಯೋಜನೆಯಡಿ ಕಾರ್ಯನಿರ್ವಹಿಸುವ ವೈದ್ಯರಿಗೆ ಮತ್ತು ದಾದಿಯರಿಗೆ ಶೇ 25 ರಷ್ಟು ವೇತನ ಹೆಚ್ಚಳ ಮಾಡಿದೆ, ಈ ಕ್ರಮದಿಂದಾಗಿ ಪ್ರಾಥಮಿಕ ಆರೋಗ್ಯ ಕೇಂದ್ರ, ಸಮುದಾಯ ಆರೋಗ್ಯ ಕೇಂದ್ರ ಮತ್ತು ತಾಲ್ಲೂಕು ಆರೋಗ್ಯ ಕೇಂದ್ರಗಳಲ್ಲಿ ಕಾರ್ಯನಿರ್ವಹಿಸುವ ವೈದ್ಯರು ಮತ್ತು ದಾದಿಯರಿಗೆ ಸ್ಫೂರ್ತಿ ಸಿಗಲಿದ್ದು ಗ್ರಾಮೀಣ ಭಾಗಗಳಲ್ಲಿ ಕಾರ್ಯ ನಿರ್ವಹಿಸಲು ಉತ್ತೇಜನ ನೀಡಿದಂತಾಗುತ್ತದೆ. ಈ ಕ್ರಮವು ಸಮಾಜದಲ್ಲಿ ಆರೋಗ್ಯ ಸುಧಾರಣೆಗಾಗಿ ಸಹಕರಿಸಲಿದ್ದು ಇದರಿಂದಾಗಿ ಸಾಮಾನ್ಯ ಜನತೆಗೆ ಸಾಕಷ್ಟು ಅನುಕೂಲವಾಗಲಿದೆ. ನನ್ನ ಮನವಿಗೆ ಸ್ಪಂದಿಸಿ ವೇತನ ಹೆಚ್ಚಳ ಮಾಡಿದ ನರೇಂದ್ರ ಮೋದಿ ನೇತೃತ್ವದ ಕೇಂದ್ರ ಸರ್ಕಾರಕ್ಕೆ ಮತ್ತು ರಾಜ್ಯ ಆರೋಗ್ಯ ಸಚಿವರಾದ ಶ್ರೀ ದಿನೇಶ್ ಗುಂಡೂರಾವ್ ಅವರಿಗೆ ತುಂಬು ಹೃದಯದ ಧನ್ಯವಾದಗಳು.
#NHM #salaryhike #doctors #nurses #centralgovt #CentralGovt
Great to see a Celebrity voicing out so succinctly his journey & fight with Metabolic syndrome using evrything available in the arsenal
#obesity#Mounjaro#weightloss
@junoesque@Humblesays@SandeepMall Would not recommend carrying and self use of a broad spectrum antibiotic or any other kind unless travelling to a remote place.They are of many kinds and have to be taken only on prescription by a Doctor for a specific issue.
What really happens when patients stop GLP-1s like semaglutide or tirzepatide?
A new systematic review & meta-analysis in Obesity Reviews has answers—and they’re critical for anyone treating obesity as a chronic disease.
TLDR: "Discontinuation of GLP-1RA treatment leads to weight regain, regardless of lifestyle interventions, and should therefore be considered a chronic therapy to prevent weight regain and associated undesirable outcomes related to obesity."
Key findings:
After stopping liraglutide, patients regained ~2.2 kg ⚖️
After stopping semaglutide/tirzepatide, patients regained ~9.7 kg ⚠️
Weight regain was proportional to initial weight loss
Lifestyle changes alone did not prevent regain
Implication:
GLP-1 receptor agonists are not a short-term solution.
If the goal is durable weight loss and risk reduction, stopping therapy may reverse progress.
We don’t stop:
Antihypertensives when blood pressure normalizes
Statins when LDL improves
Why treat obesity differently?
This study reinforces what many of us already know:
Obesity is chronic. GLP-1 therapy should be chronic too.
Let’s treat it that way.
Full article: https://t.co/sqKxsLe2lI
#Healthcare is not a luxury, but an essential which rich & poor need alike. India's budgetary allocation towards healthcare fell below 2% in last 3 yrs against 2% & more during FY17 to FY22. I hope, in #UnionBudgetFY26 we will see a weighty allocation in healthcare. @nsitharamanoffc@FinMinIndia
https://t.co/MqmKi8TNUt
Read this searing article by Bibek Debroy, he is no more. The most hard-hitting stuff you would read this month. Re-prioritise your life please. Must read.
Full article link: https://t.co/RQKac1ZfhF